NCT06245330View on ClinicalTrials.gov

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Solid TumorPancreatic Cancer
Interventions
DRUG

AST-001

liquid formulation for Intravenous infusion

Trial Locations (1)

130000

RECRUITING

Jinlin Cancer Hospital, Changchun

Sponsors
All Listed Sponsors
lead

Ascentawits Pharmaceuticals, Ltd

INDUSTRY

NCT06245330 - A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter